Study of Efficacy, Safety of Fulranumab Adjunctive Use in OA of Hip or Knee, PAI3001
Phase 3
Completed
- Conditions
- OsteoarthritisPain
- Interventions
- Drug: Fulranumab 1 mgDrug: Fulranumab 3 mgDrug: PlaceboDrug: Opioid
- First Posted Date
- 2015-01-13
- Last Posted Date
- 2017-10-02
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 79
- Registration Number
- NCT02336685
Study of Efficacy, Safety of Fulranumab Monotherapy for OA of Hip or Knee, PAI3002
Phase 3
Completed
- Conditions
- PainOsteoarthritis
- Interventions
- Drug: Fulranumab 1 mgDrug: PlaceboDrug: Fulranumab 3 mg
- First Posted Date
- 2015-01-13
- Last Posted Date
- 2017-10-02
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 18
- Registration Number
- NCT02336698
A Study to Evaluate Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of the Combination of Ibrutinib With Nivolumab in Participants With Hematologic Malignancies
- First Posted Date
- 2015-01-01
- Last Posted Date
- 2023-06-15
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 144
- Registration Number
- NCT02329847
Efficacy and Safety Study of Guselkumab in the Treatment of Participants With Active Psoriatic Arthritis (PsA)
Phase 2
Completed
- Conditions
- Psoriatic Arthritis
- Interventions
- First Posted Date
- 2014-12-18
- Last Posted Date
- 2020-10-14
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 149
- Registration Number
- NCT02319759
A Study to Evaluate 3 Dose Schedules of Daratumumab in Participants With Smoldering Multiple Myeloma
- First Posted Date
- 2014-12-12
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 123
- Registration Number
- NCT02316106
Study of Safety, Efficacy of Fulranumab Adjunctive Use in OA of Hip or Knee, PAI3007
Phase 3
Completed
- Conditions
- OsteoarthritisPain
- Interventions
- Drug: PlaceboDrug: Fulranumab 1 mgDrug: Fulranumab 3 mgDrug: Celecoxib 100 mg Matching PlaceboDrug: Celecoxib 100 mg
- First Posted Date
- 2014-11-25
- Last Posted Date
- 2017-09-14
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 111
- Registration Number
- NCT02301234
Study to Evaluate the Janssen Autism Knowledge Engine in Children and Adults With Autism Spectrum Disorder
Completed
- Conditions
- Autism Spectrum Disorder
- Interventions
- Other: No Intervention
- First Posted Date
- 2014-11-24
- Last Posted Date
- 2017-10-23
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 34
- Registration Number
- NCT02299700
A Study to Evaluate Safety and Efficacy of Toreforant (JNJ-38518168) in Participants With Moderate to Severe Plaque-type Psoriasis
Phase 2
Completed
- Conditions
- Psoriasis
- Interventions
- Drug: JNJ-38518168 30 mgDrug: JNJ-38518168 60 mgDrug: JNJ-38518168 3 mgDrug: Placebo
- First Posted Date
- 2014-11-20
- Last Posted Date
- 2017-07-07
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 62
- Registration Number
- NCT02295865
An Observational Study of Infliximab in Participants Suffering From Ankylosing Spondylitis With Hip Involvement
- First Posted Date
- 2014-11-18
- Last Posted Date
- 2017-11-01
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 76
- Registration Number
- NCT02293681
A Study to Compare the Safety of Rivaroxaban Versus Acetylsalicylic Acid in Addition to Either Clopidogrel or Ticagrelor Therapy in Participants With Acute Coronary Syndrome
Phase 2
Completed
- Conditions
- Acute Coronary Syndrome
- Interventions
- First Posted Date
- 2014-11-18
- Last Posted Date
- 2017-12-26
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 3037
- Registration Number
- NCT02293395
© Copyright 2025. All Rights Reserved by MedPath